Aktienanalyse zu OS Therapies Inc (OSTX)OSTXOS Therapies Inc

OS Therapies Incorporated is a clinical-stage oncology company focused on the identification, development, and commercialization of new class immunotherapy candidates for solid tumors, beginning with osteosarcoma and other solid tumors. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer. It operates in the Healthcare sector.

OS Therapies Inc (OSTX) is currently trading at $1.25, significantly below its 52-week high of $2.25, indicating potential for recovery. However, the RSI is at a low 24.41, suggesting the stock is oversold, which could indicate a buying opportunity. The forward P/E ratio is 1.66, which is relatively low, but the company has reported substantial losses, with a net income loss of $13.5 million expected in Q4 2025. The main risk is the company's ongoing financial struggles, as evidenced by a current ratio of only 0.18, indicating liquidity issues.